PEN Penumbra, Inc.
USHealthcareAs of 2026-07-10 16:00
Why PEN matters now
Penumbra, Inc. (PEN) is a US stock in Healthcare. The latest InvestLog snapshot shows $318.10 with +0.05% on the session and $12.51B in market capitalization; recent performance reads 1-month -2.86% and YTD +2.02%.
The latest financial table shown here is Q1 2026, with revenue of $374.8M, net income of $32.6M, and EPS of $0.82. Investors can compare that operating picture with valuation signals such as P/E 72.87 and FCF yield 1.7%.
The latest indexable market news headline is "First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $374.00; recent insider activity includes Elsesser Adam filing G-Gift. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
72.87
PEG
0.06
P/B
8.45
P/S
8.58
EV/EBITDA
56.35
DCF Value
$-105.89
FCF Yield
1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
67.4%
Operating Margin
12.9%
Net Margin
11.8%
ROE
12.3%
ROA
9.0%
ROIC
9.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $374.8M | $32.6M | $0.82 |
| Q4 2025 | $385.4M | $47.3M | $1.20 |
| FY 2025 | $1.40B | $177.7M | $4.52 |
| Q3 2025 | $354.7M | $45.9M | $1.17 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$368.18
Target (Median)
$374.00
Target Range
$335.00 - $374.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.70
Penumbra, Inc., founded in 2004 and headquartered in Alameda, California, is a global medical device company specializing in the design, development, manufacture, and sale of innovative healthcare products. The company offers a comprehensive portfolio addressing a wide range of medical needs, particularly in neurovascular and peripheral vascular interventions. Its offerings include advanced aspiration-based thrombectomy systems like the Penumbra System, marketed under various brands such as Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE, which are designed for mechanical thrombectomy, along with the Indigo System for broader vascular applications. For neurovascular conditions, Penumbra provides embolization coiling systems, including the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil, used to treat aneurysms and other neurovascular lesions. Additionally, they offer neurovascular access systems, such as Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM, which enable intracranial access for various therapies. The product line also features neurosurgical aspiration tools like the Artemis Neuro Evacuation Device for tissue and fluid removal, and detachable embolic coil systems (Ruby Coil and Ruby LP) for peripheral embolization. Furthermore, Penumbra supplies microcatheters under the LANTERN brand for delivering coils and occlusion devices, as well as detachable, microcatheter-deliverable occlusion devices (POD – Penumbra Occlusion Device) primarily for occluding peripheral vessels. Complementary devices like Packing Coil and Packing Coil LP are also available for vessel occlusion. Beyond interventional devices, Penumbra develops immersive computer-based technologies for therapeutic purposes, such as the Real Immersive System, which aims to promote health, motor function, and cognitive improvement. The company distributes its products internationally through both its dedicated direct sales organizations and a network of distributors.